denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Research, Diseases, Real-world evidence, Myeloid Malignancies
Background & aim: SH2B3 is a gene involved in cell proliferation by negatively regulating the TPO/MPL/JAK2 pathway. Up to 7% of myeloproliferative neoplasms present mutations in this gene. However, the prevalence, prognosis, and mechanism of action of SH2B3 mutations in myelodysplastic neoplasms (MDS) are unknown. The study aimed to analyze the clinical characteristics and prognostic impact of SH2B3 mutations in patients with MDS.
Methods: We included patients with MDS and chronic myelomonocytic leukemia dysplastic variant (CMML-MD) according to 2017 WHO criteria. The study group comprised patients with mutations in the SH2B3 gene with a variant allele frequency (VAF) < 40% or VAF ≥ 40% if the germline origin was excluded (MDS-SH2B3mut). As a control group, we included MDS and CMML-MD patients without SH2B3 mutations (MDS-SH2B3wt). Clinical and biological characteristics were collected at diagnosis. Genetic profiling included G-banding cytogenetics and NGS for the analysis of mutations in myeloid-related genes. The Revised and Molecular International Prognostic Scoring System (IPSS-R and IPSS-M) were employed for patients’ risk stratification. Clinical and molecular variables were evaluated for associations with progression to acute myeloid leukemia (AML) and overall survival (OS). Clinical and molecular parameters, along with outcomes, were compared between MDS-SH2B3mut and MDS-SH2B3wt groups. Statistical analysis was performed using R (version 4.2.2).
Results: A total of 245 MDS patients were included: 84 SH2B3mut patients from 18 international institutions and 161 MDS-SH2B3wt patients from 2 institutions. The median follow-up for the entire cohort was 27 months (95%CI 19–34). The median age of the overall cohort was 75 years (IQR, 68–82) and 62% (n=152) were male. Obtained from 2 institutions, the observed prevalence of SH2B3 mutations was 3% (5 out of 166). There were not significant differences in age, sex, bone marrow blasts and blood counts between MDS-SH2B3mut and MDS-SH2B3wt patients. However, more CMML-MD patients were allocated in the MDS-SH2B3mut group (19% vs 4%; p <0.01). Conversely, more MDS-multilineage dysplasia and MDS-excess blasts-2 were present in the MDS-SH2B3wt group (40% vs 24%; p=0.01, and 16% vs 6%; p=0.03; respectively). Considering cytogenetics, patients with MDS-SH2B3mut presented less frequently high and very-high IPSS-R cytogenetics risk groups than those with MDS-SH2B3wt (2% in MDS-SH2B3mut and 16% in SH2B3wt patients; p<0.01). Therefore, MDS-SH2B3mut patients were less frequently categorized into the high and very-high IPSS-R risk groups than MDS-SH2B3wt patients. Specifically, only 10% of MDS-SH2B3mut patients fell into the high and very-high IPSS-R risk groups, compared to 25% of MDS-SH2B3wt patients (p<0.01). There were no significant differences in the IPSS-M classification between the two subgroups. Of note, MDS-SH2B3mut patients presented higher frequencies of ZRSR2 (20% vs. 8%; p=0.01), SRSF2 (28% vs. 9%; p<0.01), and TET2 (55% vs. 35%; p<0.01) mutations compared to MDS-SH2B3wt.
Patients with MDS-SH2B3mut exhibited better outcomes compared to patients with MDS-SH2B3wt. The median OS for patients with MDS-SH2B3mut was of 90 months (CI95% 62–NR), whereas it was of 51 months (95% CI: 31–95) for patients with MDS-SH2B3wt (p=0.05). Additionally, 0% of MDS-SH2B3mut and 16% of MDS-SH2B3wt patients progressed to AML at 60 months (HR 3.7; CI95% 1–14; p=0.02). Furthermore, the favorable outcomes associated with SH2B3 mutations were maintained even in patients within the high- and very IPSS-R score. In the multivariate analysis including SH2B3 mutation and the IPSS-R, SH2B3 mutation (HR 0.4; CI95% 0.2–0.9) and lower-risk categories (IPSS-R <3.5 points) (HR 0.3; CI95% 0.2–0.5) were identified as independent factors for better survival. Finally, in the multivariate model including SH2B3 mutation and the IPSS-M, SH2B3 mutation (HR 0.5; CI95% 0.3–1) and IPSS-M very-low risk category (HR 0.1; CI95% 0.1–0.6) were identified as independent factors for better survival.
Conclusions: Our study, the first to describe a cohort of MDS patients with SH2B3 mutations, revealed that MDS-SH2B3mut patients exhibit distinctive characteristics, including favorable outcomes and an enrichment of mutations in splicing factor genes. These findings could have significant implications for guiding treatment decisions.
Disclosures: Metzeler: BMS/Celgene: Consultancy, Honoraria; Menarini Stem Line: Honoraria; AstraZeneca: Honoraria; Otsuka: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Servier: Honoraria; Astellas: Honoraria; Abbvie: Honoraria, Research Funding; Sysmex: Honoraria. Jerez: Aztrazeneca: Research Funding; GILEAD: Research Funding; Novartis: Consultancy; BMS: Consultancy. Díaz-Beyá: BMS: Consultancy; Jazz Pharmaceuticals: Consultancy; Novartis: Consultancy; Takeda: Consultancy; Abbvie: Consultancy. Diez-Campelo: BLUEPRINT MEDICINES: Consultancy, Membership on an entity's Board of Directors or advisory committees; AGIOS: Consultancy, Membership on an entity's Board of Directors or advisory committees; KEROS: Honoraria, Membership on an entity's Board of Directors or advisory committees; CURIS: Membership on an entity's Board of Directors or advisory committees; SYROS: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Other: Travel reimbursement; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory board fees; HEMAVAN: Membership on an entity's Board of Directors or advisory committees; ASTEX/OTSUKA: Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL TO MEETINGS. Sallman: Agios: Consultancy; Abbvie: Consultancy; Axiom: Consultancy; Gilead: Consultancy; Celyad: Consultancy; Froghorn: Consultancy; Incyte: Consultancy; Intellisphere, LLC: Consultancy; Johnson & Johnson: Consultancy; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees; Magenta Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; NextTech: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; AvenCell: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; BlueBird Bio: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Dark Blue Therapeutics: Membership on an entity's Board of Directors or advisory committees; Intellia: Membership on an entity's Board of Directors or advisory committees; Jasper Therapeutics: Membership on an entity's Board of Directors or advisory committees; NKARTA: Membership on an entity's Board of Directors or advisory committees; Orbital Therapeutics: Membership on an entity's Board of Directors or advisory committees; Rigel Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Apera: Research Funding; Jazz: Research Funding. Bosch: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; TG Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Advantage Allogene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Enterome: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Lava Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Lilly: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Celgene/BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Mundipharma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony. Germing: BMS: Honoraria; Novatis: Honoraria; JAZZ: Research Funding; BMS: Research Funding; Abbvie: Research Funding. Platzbecker: Amgen: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; MDS Foundation: Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Research Funding; Curis: Consultancy, Honoraria, Research Funding; Geron: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Novartis: Consultancy, Research Funding. Fenaux: BMS: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Servier: Research Funding; Astex: Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; Novartis: Research Funding; Janssen: Research Funding; Agios: Research Funding. Garcia-Manero: Merck: Research Funding; H3 Biomedicine: Research Funding; Janssen: Research Funding; Curis: Research Funding; Forty Seven: Research Funding; Helsinn: Research Funding; Amphivena: Research Funding; Aprea: Research Funding; Astex: Other: Personal fees; Genentech: Research Funding; Onconova: Research Funding; Astex: Research Funding; Bristol Myers Squibb: Other: Personal fees, Research Funding; AbbVie: Research Funding; Novartis: Research Funding; Helsinn: Other: Personal fees; Genentech: Other: Personal fees. Komrokji: Rigel: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; DSI: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genentech: Consultancy; BMS: Research Funding; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy; Keros: Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servio: Honoraria; CTI biopharma: Membership on an entity's Board of Directors or advisory committees; Geron: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sumitomo Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Taiho: Membership on an entity's Board of Directors or advisory committees; Servio: Membership on an entity's Board of Directors or advisory committees. Valcarcel: MSD: Consultancy, Honoraria, Speakers Bureau; Jazz Pharmaceuticials: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Gebro: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; AbbVie: Consultancy, Other: Meeting and travel accommodation; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Research Funding, Speakers Bureau; SOBI: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; Servier: Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Agios: Honoraria, Other: Meeting and travel accommodation, Speakers Bureau; Kite/Gilead: Consultancy, Honoraria, Speakers Bureau; TAKEDA: Consultancy, Honoraria, Speakers Bureau; Sanofi: Consultancy, Honoraria, Other: Meeting and travel accommodation, Speakers Bureau; Grifols: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau.
See more of: Oral and Poster Abstracts